PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-02-03

Date Title Company
03-Feb-2025 Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development AccessWire
03-Feb-2025 Automated Breast Ultrasound Systems Market to Reach USD 7.23 Billion by 2033 at a 14% of CAGR, Driven by Rising Breast Cancer Screening Demand MARKITWIRED
03-Feb-2025 Automated CPR Device Market to Reach USD 255.7 Million by 2034 at a 5.4% of CAGR, Driven by Rising Cardiovascular Cases and Technological Advancements MARKITWIRED
03-Feb-2025 Continuous Glucose Monitoring (CGM) Market to Reach USD 103.5 Billion by 2033 at a 25.1% of CAGR, Driven by Technological Advancements MARKITWIRED
03-Feb-2025 China’s First Aid Market Poised for Steady Growth Amid Rising Demand for Wound Care Solutions MARKITWIRED
03-Feb-2025 High Content Screening Market Set for Robust Growth USD 3 Billion with a 5.8% of CAGR, Expanding Drug Discovery Applications MARKITWIRED
03-Feb-2025 From Wheelchair to Hope: Marjorie's Journey to Walking Again With the Spero Clinic AccessWire
03-Feb-2025 New sustainable plant-based membrane works without fossil-fuel materials and toxic solvents University of Bath
03-Feb-2025 CHMP recommends subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer Janssen-Cilag International NV
03-Feb-2025 Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler SE's Communication Channels Eckert & Ziegler SE
03-Feb-2025 First Participants Vaccinated with IAVI’s Ebola Sudan Vaccine Candidate in Uganda Amid Ebola Outbreak AccessWire
03-Feb-2025 BiocSol secures additional €4.4M to develop its sustainable crop protection solutions Andrew Lloyd Associates
03-Feb-2025 CHMP recommends subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer Janssen-Cilag International NV
03-Feb-2025 Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025 AccessWire
03-Feb-2025 DEXIS Reflects on a Year of Innovation and Unveils Exciting Plans for 2025 AccessWire
03-Feb-2025 Aplagon Announces EUR 7 Million Financing to Advance its APAC Therapeutic for Thrombo-Inflammatory Diseases into Phase 2A Clinical Trials Aplagon
03-Feb-2025 Terclara (MOB-015) is now being launched in Norway Moberg Pharma AB
03-Feb-2025 Sanofi announces buy back of shares from L’Oréal Sanofi
03-Feb-2025 MODERNA WAS THE LARGEST INDUSTRY SPONSOR OF CLINICAL TRIALS IN THE UK IN 2023/24 AS CONSTRUCTION ON MODERNA INNOVATION AND TECHNOLOGY CENTRE IN OXFORDSHIRE NEARS COMPLETION MODERNA
03-Feb-2025 Cold Chain Technologies and Tower Cold Chain Celebrate Landmark Sustainability Achievements Cold Chain Technologies